Medical device company Orthos has received funding of £835,000 to bring its mouldable bone substitute to market.

Medical device company Orthos has received funding of £835,000 to bring its mouldable bone substitute to market.

The South Wales-based company received the bulk of the money from Finance Wales, which contributed £500,000 in equity finance, and the Welsh Assembly Government, which provided a grant of £275,000. The balance of £60,000 was supplied by business angel investors.

Orthos has also appointed Robert Welsh as chief executive and Christina Doyle as a non-executive director. Welsh is the former managing director of orthopaedic device developer Corin, while Doyle is chief executive of technology commercialisation company Xeno Medical.

Richard Thompson, early stage investment manager at Finance Wales, says Orthos has established relationships with a number of universities to develop its intellectual property.

He adds, ‘It also has a track record of identifying and developing innovative orthobiologic products, a number of which are already on sale.’

Founded by Alan Rorke in 1998, Orthos recently relocated from Bristol to Cwmbran.